Dong-A Socio Holdings Absorbs Dong-A Pharmaceutical, Becoming Operating Holding Company to Close Valuation Gap

[Korea Financial Times, Jeong Chaeyun] Dong-A Socio Holdings is formally launching as an "operating holding company" after absorbing its wholly owned subsidiary Dong-A Pharmaceutical. By bringing the group's key cash cows, Bacchus and over-the-counter (OTC) drugs, inside the holding company, it aims to build up its fundamentals. It also plans to resolve the chronic holding company discount by linking the business value of a profitable unlisted subsidiary to the listed holding company.

Back Together After 13 Years: Shifting to an 'Operating Holding Company'

According to industry sources on Oct. 1, Dong-A Socio Holdings completed its small-scale merger with Dong-A Pharmaceutical that day. It is now operating as an operating holding company under the new name of the merged entity, "Dong-A Pharmaceutical."

The surviving legal entity is Dong-A Socio Holdings, but the merged company's name changes to Dong-A Pharmaceutical through an amendment to its articles of incorporation. The amendment, which changes the company name and adds business purposes, took effect after an extraordinary shareholders' meeting on Sept. 22.
When Dong-A Socio Group converted to a holding company structure in 2013, it split into Dong-A Socio Holdings as the holding company, Dong-A ST as the prescription drug (ETC) business, and Dong-A Pharmaceutical as the OTC and Bacchus business. Since then, Dong-A Socio Holdings has served as a pure holding company focused on managing and investing in its subsidiaries' shares.

However, a pure holding company structure has the drawback that the holding company's own earnings become more volatile depending on its subsidiaries' business performance and dividend payout ratios. Its capacity to generate capital through its own operations is also limited, which has drawn criticism that capital allocation is inefficient when making large investments such as finding new growth drivers or acquiring promising biotech ventures.

The launch of the merged company is seen as a move to confront these structural constraints head-on. As Dong-A Pharmaceutical's operating assets and earnings base are absorbed directly into the holding company, the holding company itself becomes an operating holding company with stable operating cash flow. Dong-A Socio Holdings already owned 100% of Dong-A Pharmaceutical before the merger, so there is no change in aggregate group results on a consolidated basis. However, the merger is expected to raise revenue and operating profit in the holding company's standalone financial statements.

Q3 Results Tailwind Reflects Solid Cash-Generating Power

The Q3 earnings outlook for Dong-A Socio Holdings, due out soon and timed to the merged company's official launch, is also positive. According to the current brokerage consensus (market average forecast), Q3 consolidated revenue is projected at KRW 423.7 billion, up 10.74% year-on-year, and operating profit at KRW 35.6 billion, up 6.89%.

The biggest contributor to these results is Dong-A Pharmaceutical, the absorbed company. Its OTC lineup of well-known products, including Bacchus, Panpyrin, Champ and Noscarna, along with growth in health functional foods such as the premium vitamin Orthomol, has demonstrated solid cash-generating ability year after year.
Dong-A Pharmaceutical's standalone operating cash flow was KRW 97.6 billion in 2023, KRW 44.5 billion in 2024 and KRW 130.7 billion in 2025. Its standalone annual revenue last year also exceeded KRW 700 billion. With this profitable cash pipeline now integrated into the holding company, its financial strength as an operating holding company is expected to improve further.

No New Shares Issued, Preserving Shareholder Value

The market sees the merger as more than a simple reallocation of resources. It regards it as a catalyst for revaluation, chiefly because of how the merger was structured and how directly asset value now flows into the parent.

Dong-A Socio Holdings absorbed Dong-A Pharmaceutical through a small-scale merger at a 1-to-0 ratio, with no new shares issued. Because no new shares are issued, there is no risk of diluting existing shareholders' stake value.

On the Korean stock market, holding company discounts have recurred, in which the real value generated by a profitable unlisted subsidiary is not properly reflected in the holding company's share price, or the company is undervalued over concerns about double listing. The no-new-share merger, however, creates a structure in which the operating value and assets of Dong-A Pharmaceutical, once fenced in as an unlisted subsidiary, are reflected directly in the listed holding company's financial statements.

This is expected to help improve the holding company's capital allocation efficiency. The internalized cash flow can be used to fund future growth drivers such as new drug development and the bio business within the group. It creates a virtuous cycle of capital between the healthcare and OTC businesses, which generate profits in the short term, and the bio research and development (R&D) business, which needs longer-term results.

"When a pure holding company converts into an operating holding company, standalone revenue and operating profit increase dramatically," said an official in the investment banking (IB) industry. "This leads to a higher credit standing for the holding company itself and greater borrowing capacity, giving the entire group financial flexibility."

Jeong Chaeyun (chaeyun@fntimes.com)